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OBJECTIVES We tested the hypothesis in patients (n 5 24) with ischemic heart disease that chronic
contractile dysfunction occurs in myocardial regions with true reduction in rest blood flow.
BACKGROUND Whether viable myocardial regions with chronic contractile dysfunction have true reduction
in rest myocardial blood flow is controversial.
METHODS Positron emission tomography (PET) 13N-ammonia was used to measure myocardial blood
flow in combination with 18F-fluorodeoxyglucose (18FDG) to assess myocardial viability.
Viability also was assessed by dobutamine echo and recovery of function after coronary artery
bypass grafting (CABG). Segments (n 5 252) were selected based on PET measured reduced
resting blood flow and rest asynergy on echo.
RESULTS Regional myocardial viability was present in 20 of 23 patients by PET, 13 of 23 by
dobutamine echo and 10 of 11 by postrevascularization criteria. Rest blood flow in normal
regions was 1.14 6 0.52 ml/min/g and by definition exceeded (p , 0.005) that in both viable
(0.48 6 0.15; n 5 8 patients) and nonviable (0.45 6 0.14; n 5 8 patients) regions
(post-CABG criteria), which did not differ. Correction of rest myocardial blood flow in viable
asynergic segments, only, for fibrosis and incomplete tracer recovery raised the level to 0.67 6
0.21 (p , 0.005 vs. normal). Finally, evidence of both stunning (rest asynergy with normal
flow) and hibernation was present in 15 of 23 (65%) patients.
CONCLUSIONS Reduced rest blood flow in viable myocardial regions with chronic asynergy is common and
cannot be accounted for by partial volume effect. Thus, hypotheses concerning physiologic
mechanisms underlying chronic contractile dysfunction should consider the role played by
chronic reduction of basal myocardial blood flow. (J Am Coll Cardiol 2000;36:2146–53) ©
2000 by the American College of Cardiology
Increased myocardial accumulation of 18F-fluorodeoxyglucose
(18FDG) relative to myocardial blood flow (i.e., “mis-
match”) in glucose-loaded patients with chronic ischemic
heart disease is an indicator of myocardial viability and the
potential for improvement of contractile dysfunction follow-
ing coronary revascularization (1,2). Although there are data
from animal experiments that indicate myocardial viability
and flow reserve are present in the setting of chronic
reduction in myocardial blood flow (3,4), data from humans
with chronic ischemic heart disease are limited (5,6). There
also is a lack of consensus and conflicting information
regarding the presence of reduced resting blood flow in
viable but chronically dysfunctional myocardium in humans
(7,8). Apparent reduction of rest myocardial blood flow in
segments with chronically impaired contraction has been
attributed to partial volume effect with resultant averaging
of flow in normal and adjacent scar tissue (9). However,
since scar: 1) does not accumulate FDG in excess of blood
flow, 2) impairs segmental contraction with dobutamine,
and 3) prevents recovery of contractile function after coro-
nary revascularization, myocardial segments composed of an
admixture of normal and scar tissue with what might be
termed pseudoreduction of rest myocardial blood flow can
be distinguished from viable segments with true chronic
reduction of blood flow and function by 1) presence of FDG
blood flow “mismatch”, 2) augmented contraction with
dobutamine, or 3) recovery of contraction after coronary
revascularization. Accordingly, the present investigation
tested the hypothesis in patients with ischemic heart disease
that chronic contractile dysfunction occurs in myocardial
segments with true reduction in rest blood flow.
MATERIALS AND METHODS
Patient population. After approval was obtained from
Human Studies Committees of the Massachusetts General
Hospital; 24 patients were recruited and gave written
informed consent between April 1, 1994 and August 30,
1996. Exclusion criteria included unstable angina, uncon-
trolled left ventricular failure or atrial fibrillation, severe
hypertension, severe chronic obstructive pulmonary disease,
or inability to lie in a supine position for sufficient time to
allow data acquisition. Patients selected for the study were
chosen based on availability of complete data set from a
larger group of patients who had been recruited for an
earlier investigation (10) because of symptomatic angina or
left ventricular failure severe enough to merit coronary
revascularization. Only those patients with left ventricular
ejection fraction ,50% and who had not had myocardial
infarction (MI) within one month of the study were
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included in the data set. Furthermore, whereas the previous
study (10) limited its attention to myocardial segments with
normal contraction at rest, the present investigation specif-
ically selected for analysis segments having reduced resting
blood flow and abnormal contraction at rest (see below).
Positron emission tomography (PET) imaging. Positron
emission tomographic imaging was performed on a whole
body tomograph (Scanditronix PC4096, GE Medical Sys-
tems, Waukesha, Wisconsin) (10–12). The electrocardio-
gram and arterial pressure (Dynamap TM; Tampa, Florida)
were continuously monitored. At baseline, ;25 mCi of
13N-ammonia was administered intravenously (IV) over
30 s, with dynamic imaging begun just prior to injection.
After image acquisition, radioactivity was allowed to decay
for approximately 30 min, at which time the count rate seen
by the scanner was sufficiently low to be overwhelmed by the
subsequent dose. Next, 2 min after starting an IV infusion
of adenosine at 140 mg/kg/min 3 5 min, dynamic data
acquisition was begun, and several seconds later, ;25 mCi
of 13N-ammonia was administered. Images were acquired as
described above. The radiation dose associated with the
13N-ammonia study was 9.2 mR/mCi whole body.
After completion of the 13N-ammonia study, the patient
was given an oral glucose load (Glucola, 100 g dextrose)
followed by ;7.5 mCi of IV 18FDG approximately 45 min
later. Diabetic patients were not glucose loaded, but instead
they were permitted to eat approximately 1 h before FDG
injection with insulin or oral agent coverage and were given
supplemental regular insulin (2 to 3 U IV) as needed if
myocardial tracer uptake was inadequate when imaging was
begun. One hour after FDG injection, the patient was
repositioned in the scanner and a single 15-min image was
obtained. After completion of the FDG scan, a second
10-min transmission scan was acquired for reconstruction of
the FDG study. Residual radioactivity in each patient was
30- to 40-fold less than the Germanium-68 pin source and
thus did not interfere with the second transmission scan.
The radiation dose associated with the 18FDG study was 39
mR/mCi whole body.
Attenuation-corrected 13N-ammonia images were recon-
structed with a filtered back projection algorithm. Scans
using the last 6 min of data were summed, and a region of
interest (ROI) was placed over the left ventricular (LV)
cavity. The ROI was used to generate the arterial input
function for the two-compartment, three-parameter tracer
kinetic model used to compute K1 (10–12). No correction
was employed for recirculation of labeled ammonia metab-
olites (13). A computer program developed at our institu-
tion used the dynamic, 9-min data set to generate paramet-
ric (K1) images for determination of myocardial blood flow
(10–12).
Dobutamine echocardiography. Dobutamine echocardi-
ography was performed, as previously reported (10), with
continuation of all medications except beta-blockers, which
were held for 24 h before study if possible. Echocardiograms
were performed within 24 to 48 h of the PET study in all
cases except six in which data were obtained within three to
eight days without change in the patient’s condition. After
baseline blood pressure (BP) and heart rate were obtained,
two-dimensional echocardiography was performed using a
2.5-MHz transducer and commercially available scanner.
Images also were digitized on-line and viewed side-by-side
in quad screen format (ImageVue DCR; NovaMicrosonic;
Indianapolis, Indiana). Echocardiography was performed in
the left lateral decubitus position and included parasternal
long and short axis views at the base (mitral), mid ventricle
(papillary muscle) and apical levels. Apical four- and two-
chamber views were also obtained. Images were recorded at
baseline and then during the final minute of each dobut-
amine infusion at doses of 5, 10, 20, 30 and 40 mg/kg/min.
Dobutamine was given up to 40 mg/kg/min dose whenever
possible. End points for termination of the infusion prior to
the 40 mg/kg/min dose included a new wall motion abnor-
mality in at least two contiguous myocardial segments,
severe anginal pain, significant hypotension (approximate
decrease in systolic BP .20 mm Hg) or malignant ventric-
ular arrhythmias. The 5- and 40-mg/kg/min doses were
given for 5 min each, while other doses were given for 3 min
each.
Image analysis. PET SCANS. Three short axis rings corre-
sponding to the proximal, middle and distal thirds of the
LV were constructed for each K1 and FDG scan (10–12).
Next, circular ROIs (;8.5 mm radius) were placed over
each ring at standard areas of interest: inferoseptum, mid-
septum, anteroseptum, anterior, anterolateral, lateral, pos-
terolateral and inferior zones. Identical ROIs were placed
over appropriately matched proximal, middle and distal
short axis rings of the FDG scan. The FDG uptake in each
ring was normalized by first determining the myocardial
region with best flow in that ring. The FDG uptake in the
zone with the best flow was set to unity, and the FDG in
other zones were normalized to it. Regional myocardial
blood flow was normalized according to the region with
highest rest blood flow in each ring. To determine if an
FDG-blood flow “mismatch” (defined as a difference
.0.35) was present, relative flow was subtracted from
relative FDG uptake (10,14).
Two groups of myocardial segments were selected to test
the study hypothesis. The reference group had: 1) normal
Abbreviations and Acronyms
ANOVA 5 analysis of variance
BP 5 blood pressure
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
18FDG 5 18F-fluorodeoxyglucose
IV 5 intravenous
LV 5 left ventricle, left ventricular
MI 5 myocardial infarction
PET 5 positron emission tomography
ROI 5 region of interest
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contraction at rest, and 2) basal, absolute myocardial blood
flow $0.39 ml/min/g and 3) basal, relative myocardial blood
flow $75% of best in a given myocardial ring. The test
group had: 1) abnormal contraction at rest, and 2) basal,
absolute myocardial blood flow ,0.80 ml/min/g and 3)
basal, relative myocardial blood flow ,75% of best in a
given myocardial ring. Criteria for the reference group was
designed to select a population of strictly normal segments
that were used to define the normal bounds for FDG uptake
relative to blood flow. An absolute value of flow $0.39
ml/min/g was chosen based on prior work from our labo-
ratory (14) that demonstrated that .95% of segments with
little or no contraction abnormality had rest myocardial
blood flow meeting these criteria. In contrast, criteria for the
test group were designed to select segments with clearly
reduced rest myocardial blood flow and contractile dysfunc-
tion.
It should be emphasized that: 1) inclusion of segments in
either normal or test groups required all three conditions for
that group to be met; 2) designation of rest myocardial
blood flow as “normal” or “abnormal” depended only on the
combination of absolute and relative flow criteria outlined
above and was entirely independent of, and could not be
altered by, contraction status of the segment; and 3)
segments that did not meet criteria for inclusion in either
the normal or test group were excluded from analysis, and
hence the total number of segments considered is ,576
(i.e.; [24 segments/Pt] 3 [24 Pts]).
DOBUTAMINE ECHOCARDIOGRAPHY. In accordance with
echocardiographic convention and as previously reported
(10), the LV was divided into 20 segments for analysis.
Short axis rings at the base, mid and distal thirds of the LV
were used. Rings at base and mid-LV levels were divided
into eight sections, each of which corresponded to those of
the PET scan. The ring at the distal third of the LV,
however, was divided into four sections (septum, anterior,
lateral and inferior). For purposes of this study, wall motion
in the septum of the distal LV ring was paired with
perfusion in septal and inferoseptal PET segments of the
distal third of the LV. Similarly, anterior wall motion was
matched with anteroseptal and anterior PET sections,
lateral wall motion with anterolateral and lateral PET
sections, and inferior wall motion with posterolateral and
inferior PET sections of the distal LV ring only.
Echocardiograms, as previously reported (10), were re-
viewed by two experienced observers who were blinded to
clinical and catheterization data. Disagreements were me-
diated by consensus. Regional wall motion scores were
determined from review of both videotape and quad screen
formatted, digitized, single cardiac cycles at baseline and
peak dose dobutamine. Each segment’s wall motion was
graded according to an ordinal scale as follows: 0 5 normal
motion; 1 5 mild hypokinesis; 2 5 severe hypokinesis; and
3 5 akinesis. Viable myocardial segments were defined by
echo criteria as having either: 1) normal contraction or only
mild hypokinesis at rest or 2) improvement in contractile
score by at least one grade with either low- or high-dose
dobutamine in segments with severe hypokinesis or akinesis
at rest. Improvement in contractile score by one grade after
coronary revascularization defined viability by post–
coronary artery bypass grafting (CABG) criteria. Postoper-
ative echos were obtained three to six months after CABG.
Cardiac catheterization. Cardiac catheterization was per-
formed by Judkins technique according to standard clinical
methods. Coronary artery stenosis diameter was measured
using combined visual and hand caliper technique by an
experienced cardiac radiologist who was unaware of results
of other imaging studies. Patients were classified as having
one-, two- or three-vessel coronary artery disease (CAD)
based on the number of coronary arteries having $70%
lumen diameter reduction.
Statistical analysis. All data are expressed as mean 6 SD.
Group mean values of hemodynamic parameters were com-
pared by one-way factorial analysis of variance (ANOVA)
and post-hoc multiple comparison test (Fishers Protected
Least Significant Difference test—StatView V4.0; Abacus
Concepts; Berkeley, California). Myocardial blood flow
parameters were compared on a patient (rather than seg-
ment) basis. This was accomplished by averaging all flow
values for a given segment type for a given patient, thereby
obtaining a single value for that type, which then was
designated a “region.” Subsequently, a repeated-measures
ANOVA (General Linear Model; SPSS 9.0 [Graduate
Pack]; Chicago, Illinois) was employed in which individual
patients (not segments) represented row values and within
subjects factors (columns) represented the flow parameters
being compared. Difference in means were tested by pair-
wise comparison only if the overall value of F was significant
at p , 0.05.
Information on PET FDG status was available in all
patients. Dobutamine stress echo data were complete in 23
of 24 patients, while post-CABG follow-up was available in
11 of 24 patients. However, because only patients with all
region types (i.e., normal, viable and nonviable) for a given
modality could be used in the repeated-measures ANOVA,
the number of patients analyzed were 15, 7 and 8 for data
obtained using PET FDG, dobutamine echo, and post-
CABG criteria, respectively, as a classifier. Differences in
frequencies of categorical variables, again using patients as
the unit of analysis, were assessed using the chi-square or
Fisher exact test.
RESULTS
Patient characteristics. The study population consisted of
22 men and 2 women (mean age, 60 6 11 years; range, 33
to 81 years) (Table 1). Prior MI was present in 17 patients.
Infarct location was anterior in 7, inferior in 3, non-Q in 2
and both anterior and inferior in 5. Triple-vessel CAD was
documented in 16 and double-vessel disease in 7 (coronary
angiography was unavailable in one patient). There were
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eight patients with diabetes in the study. Patient medica-
tions are shown in Table 1.
Hemodynamics. Baseline heart rate, systolic arterial pres-
sure and rate pressure product did not differ significantly
between PET and echo studies (Tables 2 and 3). Although
there was a trend for heart rate and rate pressure product to
increase versus baseline in response to adenosine in the PET
study (Table 2), the changes did not reach statistical
significance. There also was no change versus baseline in any
hemodynamic parameter in response to low-dose dobut-
amine (Table 3). In contrast, both heart rate and rate
pressure product increased significantly (p , 0.0001) versus
baseline in response to high-dose dobutamine. Separation of
patients receiving (n 5 9) and not receiving (n 5 15)
beta-blockers, as anticipated, demonstrated that both heart
rate and rate pressure product were 20% to 25% lower on
average at each phase of the echo study in those patients
receiving beta-blockers (data not shown). Systolic arterial
pressure, however, did not differ significantly between those
receiving and not receiving beta-blockers at any stage of the
echo study.
Patient-based analysis. MYOCARDIAL BLOOD FLOW. A to-
tal of 252 segments (23 patients [1 patient did not have any
abnormal segments meeting entry criteria]) met study cri-
teria for chronic contractile dysfunction and reduced resting
blood flow (Table 4 and Fig. 1). An additional 126
segments (23 patients) demonstrated chronic contractile
dysfunction but with normal resting blood flow (i.e.,
stunned myocardium). Postcoronary revascularization
follow-up was available in 10 of 23 patients with stunned
myocardial regions; 6 of 10 demonstrated evidence of
recovery of regional function by echocardiography.
It is apparent from Table 4 and Figure 1 that rest
myocardial blood flow in viable and nonviable regions,
considered on a patient-by-patient basis, did not differ
significantly regardless of criteria employed to determine
viability. Furthermore, by definition, rest blood flow in
reference regions exceeded that of both viable and nonviable
zones. Correction of rest myocardial blood flow in viable
regions only, for partial volume effects related to fibrosis
(12%, vide infra) and incomplete tracer recovery (30% [15]),
increased the value to the range of 0.59 6 0.22 to 0.67 6
0.21 depending on viability criteria chosen (i.e., PET vs.
post-CABG). Either value, however, was reduced (p ,
0.005) versus matched patient regions with normal rest flow
(range, 0.99 6 0.51 to 1.09 6 0.47).
Myocardial flow reserve expressed either as the ratio of
adenosine to rest flow or the absolute difference between
adenosine and rest flow was markedly reduced and did not
differ among region types regardless of criteria employed to
define viability. There was a tendency for reference regions
to have greater absolute increment in flow with adenosine;
but patient-to-patient variation was substantial, and the
differences failed to reach statistical significance. The great
majority of normal (;85%), abnormal viable (.95%) and
nonviable (.95%) regions, regardless of criteria employed
to define viability, were distal to a coronary stenosis of
$70% lumen diameter reduction.
DOBUTAMINE ECHOCARDIOGRAPHY. The distribution of
basal contractile abnormalities was as follows: 35 of 252
(14%, 17 patients), mild hypokinesis; 62 of 252 (25%, 20
patients), severe hypokinesis; and 155 of 252 (62%, 22
patients), akinesis. Only 4 of 19 (21%) patients had echo
viable akinetic regions versus 6 of 8 (75%) with severe
hypokinesis (chi-square 5 4.98, p , 0.05). The vast
majority ($95%) of echo viable and nonviable regions were
in the distribution of a hemodynamically significant coro-
nary stenosis. Presence or absence of beta-blocker therapy
did not correlate with contractile response to dobutamine.
The FDG blood flow mismatch was present in 2 of 3
patients having an average abnormal region exhibiting mild
hypokinesis, 4 of 8 with severe hypokinesis and 14 of 19
Table 2. Hemodynamics (Mean 6 SD)—Positron Emission
Tomographic Study
Rest Adenosine
HR 72 6 15 79 6 22
SAP 122 6 13 115 6 15
RPP 8,730 6 2,003 9,033 6 2,633
HR 5 heart rate (/min); SAP 5 systolic arterial pressure (mm Hg); RPP 5 rate
pressure product (mm Hg/min).
Table 3. Hemodynamics (Mean 6 SD)—Dobutamine Echo
Study
Rest Lo-Dbtmn Hi-Dbtmn
HR 74 6 17 74 6 18 121 6 25*
SAP 120 6 15 117 6 16 126 6 17†
RPP 8,905 6 2,389 8,587 6 2,339 15,323 6 3,616*
Hi-Dbtmn 5 high dose dobutamine.
*p , 0.0001 vs. rest and low dose dobutamine (Lo-Dbtmn); †p , 0.06 vs. low
dose dobutamine.
Abbreviations same as for Table 2.
Table 1. Characteristics of Study Population
No. 24
Men 22
Women 2
Mean age 6 SD (range) 60 6 11 (33–81 yr)
Ejection fraction (mean 6 SD) 0.28 6 0.101 1
Prior myocardial infarction
Q-wave 15
Non-Q-wave 2
Coronary artery disease*
Three vessel 16
Two vessel 7
Prior coronary artery bypass/PTCA 4
Medications (No. of patients)
Beta-blockers 9
ACE inhibitors 19
Nitrates 12
Calcium channel blockers 4
Digoxin 11
*Coronary angiography unavailable in one patient.
PTCA 5 percutaneous transluminal angioplasty; ACE-inhibitors 5 angiotensin-
converting enzyme inhibitors.
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with akinesis (Fisher Exact Test; p 5 0.61). Though the
overall concordance between echo and FDG viability crite-
ria was poor (x2 5 0.01, p 5 NS), evidence of myocardial
viability by echo criteria was present in 8 of 20 patients
having an abnormal region exhibiting mismatch pattern and
8 of 22 with match pattern (p 5 NS). Finally, because
different individuals contributed to each region type, a total
of 13 of 23 patients had an abnormal region meeting echo
criteria for viability, 20 of 23 met PET FDG criteria and 10
of 11 met post-CABG criteria.
DISCUSSION
Hypothesis and major findings. This study tested the
hypothesis in patients with chronic ischemic heart disease
that chronic contractile dysfunction occurs in myocardial
regions with true reduction in rest blood flow. Myocardial
segments selected for analysis had rest blood flow that was
reduced versus normal by ;60% (uncorrected), and all had
echo evidence of systolic dysfunction. The FDG blood flow
mismatch was present in 20 of 23 patients. Several studies
have shown mismatch and echo viable segments have only
limited (3% to 23%; average approximately 12%) scar
component (16–18). Although myocardial segments made
up of equal parts normal and scar tissue might appear to
have rest blood flow half normal with 13N-ammonia PET
methodology, such segments do not accumulate FDG in
excess of flow and so exhibit matched FDG blood flow
defect (19,20). Moreover, as noted above, viable segments
on average have only approximately 12% fibrosis. Accord-
ingly, the presence of FDG blood flow mismatch in a
segment with reduced myocardial blood flow provides
strong evidence that the flow reduction reflects a transmural
decline in otherwise viable tissue and not pseudoreduction
related to an admixture of scar and normal muscle. Further-
more, confirmation of myocardial viability by recovery of
contractile function after coronary revascularization pro-
vided values of flow very similar to those observed in PET
or dobutamine echo viable regions.
In the present investigation, evidence of true reduction in
rest myocardial blood flow was present in at least 50% of
patients having myocardial segments with chronic contrac-
tile dysfunction meeting study entry criteria. Thus, 13 of 23
Figure 1. Bar plot of rest myocardial blood flow (MBF) (Qrst; mean 1 SD) as a function of criteria employed to determine myocardial viability. It is
apparent that values are comparable (and do not differ significantly across methods) regardless of criteria used. Normal (reference) zone (NZ) Qrst by
definition is significantly greater (p , 0.005) than that of either viable (VBL) or nonviable (NVBL) low flow regions, which do not differ.
Table 4. Regional Myocardial Blood Flow (ml/min/g; Mean 6 SD) by Viability Criteria
Rest Ado Ratio Delta
Number of
Patients
PET-13NH3/FDG
Reference 0.99 6 0.51 1.12 6 0.53 1.27 6 0.68 0.33 6 0.67 15
Mismatch 0.36 6 0.14* 0.44 6 0.17* 1.41 6 1.00 0.07 6 0.21 15
Match 0.43 6 0.17* 0.47 6 0.13* 1.28 6 0.68 0.04 6 0.19 15
Dobutamine echo
Reference 0.96 6 0.30 0.94 6 0.28 1.01 6 0.25 20.02 6 0.28 7
Viable 0.46 6 0.14* 0.45 6 0.12* 1.07 6 0.51 20.01 6 0.17 7
Nonviable 0.44 6 0.18* 0.51 6 0.14† 1.27 6 0.49 0.07 6 0.15 7
Post-CABG recovery
Reference 1.14 6 0.52 1.26 6 0.54 1.20 6 0.40 0.12 6 0.39 8
Viable 0.48 6 0.15* 0.47 6 0.24* 0.97 6 0.48 20.01 6 0.19 8
Nonviable 0.45 6 0.14* 0.49 6 0.15† 1.09 6 0.26 0.03 6 0.10 8
*p , 0.005 vs. reference; †p , 0.01 vs. reference.
Ado 5 adenosine; Ratio 5 myocardial blood flow: adenosine/rest; Delta 5 myocardial blood flow: adenosine 2 rest; FDG 5
fluorodeoxyglucose; CABG 5 coronary artery bypass grafting.
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patients had reduced resting blood flow in dobutamine
echo-defined viable regions, 20 of 23 in PET-defined viable
regions and 10 of 11 in postrevascularization echo-defined
viable regions. The reduction in flow as noted above was
substantial (;60% uncorrected and ;40% after correction
for fibrosis) and greater than that which could be accounted
for by physiologic or methodologic variation (11). The
difference between viable segments with reduced rest myo-
cardial blood flow, however defined, and those with normal
flow also remained significant after correction for fibrosis.
Viability assessment—PET versus dobutamine echo.
The concordance between dobutamine echo and FDG
blood flow assessment of myocardial viability was approxi-
mately 50% in the present study, a result comparable to that
reported by others both for PET FDG (21) and thallium
(22,23). Indeed, in the report of Gerber et al. (21), the
authors noted that none of the FDG parameters employed
were useful in predicting the myocardial contractile response
to low-dose dobutamine. In the present study, beta-blocker
therapy did not influence response to dobutamine in seg-
ments with rest asynergy nor did coronary angiographic
stenosis severity, because most patients had triple-vessel
disease.
Apparent discordance between metabolic and contractile
markers of viability may relate to previously discussed
factors such as tethering and segment alignment (7,24,25) as
well as the fact that the majority of segments in the present
study exhibited severe hypokinesis or akinesis (25% and
62%, respectively, total 5 87%). Discordance of metabolic
and contractile markers of myocardial viability is more
common in segments with severe wall motion abnormality
(23,26).
Literature review. Apparent discordance between results
of the present investigation and prior studies indicating that
rest myocardial blood flow is normal or nearly so in
segments with chronically impaired contractile function
(20,21,27) may reflect a number of factors. First, as noted by
others (7,8), comparison of rest myocardial blood flow in
regions of chronic dysfunction to that in myocardium of
healthy, often younger, volunteers may be misleading. If a
remote region of the heart is used as the reference standard,
then several studies have shown that rest myocardial blood
flow may be reduced in segments with chronic asynergy
(6,28–30). Each of these studies, however, is vulnerable to
partial volume effect criticism. Second, the 15O-water
method used to assess myocardial blood flow (27) tends to
overestimate flow at levels below 0.5 ml/min/g (figure 10 of
reference 31) (8,31). In addition, the physiologic meaning of
perfusable tissue index (27) has been questioned and may
reflect flow heterogeneity in a tissue volume rather than
absence of water exchange between blood and infarct tissue
(32).
Third, selection criteria may play a role. At least one
study chose patients with collateral dependent myocardium
(21), which may have weighted results toward either normal
or only mildly reduced resting blood flow. In contrast, the
present investigation selected segments with reduced resting
blood flow and then applied FDG, dobutamine echo or
postrevascularization criteria to define myocardial viability
and thereby distinguish pseudo from the true flow reduction
in patients with impaired LV systolic function. If the
hypothesis had been correct that chronic contractile dys-
function does not occur in viable myocardial regions with
reduced resting blood flow, then we should have found few,
if any, patients with such regions. In point of fact, we found
many (13 of 23 by echo, 20 of 23 by PET and 10 of 11 by
post-revascularization criteria). Further, viable regions with
chronic contractile dysfunction had reduced resting blood
flow with frequency at least comparable to that of regions
with chronic asynergy and normal resting blood flow (i.e.,
stunning, 6 of 10 patients). The data obtained demonstrate,
therefore, that both stunning and hibernation may be
present in the same patient (15 of 23 in the current study)
at the same time.
Myocardial flow reserve and viability. In the present
study, myocardial flow reserve was negligible in both viable
and nonviable regions (regardless of viability criteria) with
rest asynergy and reduced resting blood flow. Accordingly,
the data indicate that the ability to augment myocardial
blood flow substantially is not an important contributor to
maintenance of myocardial viability.
The increase in myocardial blood flow required to mount
a positive response (i.e., improvement in contraction) to
dobutamine stimulation is not large in segments with
normal baseline contraction (10). In a study involving
abnormal segments, the average increase in myocardial
blood flow with dobutamine in mismatch regions was 0.20
ml/min/g from baseline flow of 0.53 6 0.33 ml/min/g (20).
However, 7 of 10 patients in that study (20) had flow
increase of #0.13 ml/min/g (average 5 0.08 6 0.03
ml/min/g), values similar to those observed with adenosine
(0.05 6 0.28) in echo-viable, mismatch segments (n 5 29)
in the present study. We have demonstrated previously that
myocardial flow response to dobutamine and adenosine is
very similar in myocardial segments with substantial impair-
ment of flow reserve (12).
Study limitations. Absence of close concordance between
FDG (or thallium) and dobutamine echo assessment of
viability has been reported by others (21), particularly in
segments with severe hypokinesis or akinesis (23). More-
over, at least one report demonstrating good agreement
between the two methods (20) was not specifically designed
for that purpose and selected a majority (6 of 10) of patients
with FDG mismatch and “positive dobutamine stress echo,”
in essence defining agreement in advance. Better concor-
dance was obtained in another study (26) in which trans-
esophageal echocardiography was employed. The later may
have improved wall motion assessment in comparison with
transthoracic echo, which was used in the present investi-
gation.
Criteria used to define FDG mismatch in the present
study were objective, and a similar approach has been
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employed previously in our laboratory (10,14). It is note-
worthy in this regard that there are no uniformly accepted
criteria for defining FDG mismatch. Some authors have
used the FDG/late ammonia retention ratio $1.2 (21),
others have employed subjective, visual grading of FDG and
late ammonia retention images (33), while others have used
delta rFDG-rMBF . 2 SD beyond the mean for normal
individuals (20). The definition used in the current study
was the same as that employed by Sun et al. (20) except for
having the cut-point at 1 SD instead of 2. Employing 2 SD
criteria would have reduced the number of mismatch seg-
ments from 100 of 252 (40%) to 53 of 252 (21%), but
application of the criteria used by Gerber et al. (21) would
have increased the number of mismatch segments to 201 of
252 (80%). Thus, the approach adopted in the current study
seeks a middle ground among competing definitions.
Correction of PET 13N-ammonia measurements of myo-
cardial blood flow for partial volume effect was performed in
this study. Absolute values of myocardial blood flow, how-
ever, were adjusted for percent fibrosis and incomplete
tracer recovery only in PET-viable segments with reduced
resting flow. Although it would have been appropriate to
correct for incomplete tracer recovery in segments with
normal resting blood flow, we chose not to do so, to be as
conservative as possible in testing the study hypothesis.
Indeed, failure to correct reference region flow for incom-
plete tracer recovery in effect corrects asynergic viable
segments for 38% fibrosis, a level comparable to that of even
the highest fraction reported in the literature (34). Further,
after correction, the difference in rest flow remained signif-
icant. The magnitude of reduction is of physiologic interest
and even at approximately 40% (vs. normal flow) corre-
sponds to levels associated with systolic dysfunction in
animal models (3,4).
Finally, assessment of myocardial viability obviously is
crucial to the conclusions of the article. Two of the methods
employed in the current study, PET and dobutamine echo,
have wide clinical acceptance and have been shown to be
reliable indicators of viability (8,24,25). Although return of
contractile function following coronary revascularization
traditionally has been regarded as the gold standard for
viability assessment, it is appreciated that 1) a variety of
technical factors (e.g., tethering) may confound these crite-
ria (35), and 2) prognosis and functional class in revascu-
larized patients is not necessarily dependent on return of
contractile function (36). Further, myocardial viability may
be defined in more than one way (37) and should not
necessarily be keyed to recovery of contractile function, for
reasons noted above. Nevertheless, we employed such cri-
teria for the 11 patients in whom this information was
available. The data obtained yielded results comparable to
PET and dobutamine echo both in terms of absolute value
(Table 3 and Fig. 1) and prevalence of reduced rest
myocardial blood flow in this clinical setting.
CONCLUSIONS
The data obtained in the present study demonstrate that
basal myocardial blood flow may be reduced substantially in
chronically asynergic regions in which myocardial viability is
present. The extent of fibrosis in such regions most often
has been reported between 3% and 24%, average approxi-
mately 12% (16–18). Thus, reduction of basal myocardial
blood flow on the order of 60% (uncorrected) in viable
myocardial regions cannot be attributed to partial volume
effect. Furthermore, in the present study, at least half the
patients had viable, chronically asynergic regions with re-
duced resting blood flow. Accordingly, hypothesis regarding
mechanisms underlying chronic myocardial asynergy in hu-
mans with ischemic heart disease should take into account
the role played by chronic reduction of rest myocardial
blood flow.
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